Troches Compounding Pharmacy: The 2026 Patient and Provider Guide to Sublingual Delivery, BHRT Formulations, and Choosing a Quality Compounder

Introduction: Why Troches Are at the Center of a Compounding Revolution in 2026

Several forces have converged in 2026 to push troches into the spotlight. Hormone replacement therapy prescriptions are up 86% since 2021, a nationwide estrogen patch shortage has disrupted transdermal delivery for countless patients, and the FDA’s November 2025 removal of the black-box warning from menopausal hormone therapy has eliminated a major psychological barrier for both patients and prescribers. Add the rapid expansion of telehealth-to-troche patient journeys, and demand for compounded sublingual lozenges has climbed sharply.

This guide takes a pharmacokinetics-first, balanced approach. Troches are not universally superior to other delivery forms. Patients and providers deserve honest clinical comparisons rather than marketing-driven oversimplification, and this article delivers exactly that.

The regulatory backdrop matters too. FDA 503A bulk substance policy changes took effect in January 2025, the “Demonstrably Difficult to Compound” list poses a real threat to certain BHRT troches, and the SAFE Drugs Act of 2025 (H.R. 6509) could reshape availability further. These are not abstract policy debates; they directly affect which troches patients can obtain.

Ahead: what troches are, how they work, BHRT formulations (Biest, progesterone, testosterone), emerging applications such as ketamine and men’s health, the telehealth patient journey, and how to evaluate a quality troches compounding pharmacy. Throughout, Nationwide Compounding Rx®, a PCAB-accredited, USP 800-compliant pharmacy with 40+ years of combined team experience, appears as a trustworthy reference point for informed decision-making.

The scale is substantial. Roughly 30 to 40 million compounded prescriptions are filled annually in the U.S., and the global compounding market was valued at $14.15 to $15.83 billion in 2025, projected to reach $19.41 to $22.57 billion by 2030 to 2033.

What Is a Troche? Anatomy, Mechanics, and How Sublingual Delivery Works

A troche is a small, flavored, slow-dissolving lozenge engineered to release active pharmaceutical ingredients gradually over 15 to 30 minutes while resting against oral mucosal tissue.

There are two primary placement sites: sublingual (under the tongue) and buccal (between the cheek and gum). Placement affects absorption rate and local drug concentration, which is why prescribers should specify one or the other.

Troches work through transmucosal absorption. Drugs pass through the thin, highly vascularized mucous membranes of the mouth directly into systemic circulation, bypassing the gastrointestinal tract and first-pass hepatic metabolism. In plain terms, when a drug is swallowed, the liver metabolizes a significant portion before it ever reaches the bloodstream, lowering effective bioavailability. Troches sidestep that pathway.

The pharmacokinetic payoff can be meaningful: onset often within minutes and higher bioavailability than an equivalent oral dose for many compounds. A typical troche base uses polyethylene glycol (PEG) or silicone-based matrices to control dissolution, plus flavoring agents that improve compliance and matter for allergen considerations.

One limitation deserves upfront mention: a clinically significant portion of the dose, especially for progesterone, is swallowed rather than absorbed buccally. That reality drives important dosing decisions covered later.

Troche Pharmacokinetics vs. Other Delivery Forms: An Honest Comparison

Troches have real advantages and real limitations. The right delivery form depends on the compound, the patient, and the clinical goal. Most competitor content lists delivery options without meaningful tradeoffs; the sections below do the opposite.

Troches vs. Oral Capsules and Tablets

Oral capsules and tablets are subject to full first-pass metabolism, with slower onset (30 to 90 minutes) and lower bioavailability for many hormones. However, they can provide more predictable, sustained serum levels for compounds that absorb well orally.

Troches offer faster onset and higher bioavailability for transmucosally absorbed compounds, but peak-and-trough fluctuations are a genuine disadvantage. Serum levels rise quickly and fall within four to five hours. For BHRT, this can cause symptom cycling, and fast metabolizers may notice symptoms returning before the next dose. Patients with dysphagia, GI absorption issues, or sensitivity to fillers and binders often strongly prefer troches. For those interested in how custom capsule compounding compares as an oral alternative, that pathway remains viable for certain compounds.

Troches vs. Transdermal Creams and Gels

Transdermal creams and gels absorb through the dermis with slower onset but more consistent, sustained delivery and less peak-and-trough variability. For progesterone specifically, creams require far lower doses (20 to 40 mg/day) than troches (200 to 400 mg/day) because troches lose a substantial portion to swallowing, a critical clinical and cost consideration.

Troches avoid skin irritation, transfer risk to partners or children, and application-site variability. Transdermal delivery offers more stable serum levels and a longer clinical track record. The 2026 estrogen patch shortage, however, has made compounded troches and creams the practical alternatives for many patients, a supply-driven shift rather than a purely clinical one.

Troches vs. Sublingual Tablets and Drops

Sublingual tablets and drops share the same transmucosal pathway but differ in dissolution time, drug-loading capacity, and patient experience. Troches can carry higher drug loads and multiple active ingredients in a single unit, making them ideal for combination BHRT (for example, Biest + progesterone + DHEA). Drops dissolve fast but offer less precise per-unit dosing; sublingual tablets dissolve quickly, potentially reducing absorption contact time. Flavor options improve troche compliance, and compounding precision matters more for solid troches, a strong argument for PCAB-accredited pharmacies.

Troches vs. Suppositories and Injectables

Vaginal or rectal suppositories deliver localized hormones and avoid first-pass metabolism but have lower patient acceptance. Injectables such as testosterone cypionate offer the highest bioavailability and most predictable pharmacokinetics, yet require administration training and produce their own peak-and-trough swings. Notably, hormone pellets were added to the FDA’s “Difficult to Compound” list in 2024, redirecting patients toward troches, creams, and capsules. Troches occupy a practical middle ground: non-invasive, self-administered, and reasonably high in bioavailability, though not the gold standard for every compound.

BHRT Troche Formulations: A Clinical Overview for Patients and Providers

BHRT is the dominant use case for compounded troches and the fastest-growing therapeutic segment in compounding, projected at a 7.86% CAGR from 2026 to 2031 and roughly 27% of market share.

“Bioidentical” means hormones molecularly identical to those the human body produces, typically derived from yam or soy and compounded to individual needs. A critical distinction: compounded BHRT is not FDA-approved, while FDA-approved bioidentical options (estradiol patches, micronized progesterone capsules) do exist. Providers must weigh both pathways.

Honesty also requires acknowledging that ACOG, ISSWSH, and the Global Position Statement recommend against compounded testosterone for women due to a lack of standardized dosing and long-term safety data. This is a clinical tension, not a blanket dismissal. Nationwide Compounding Rx® adjusts BHRT formulas at each refill based on updated lab results, supporting truly personalized hormone management.

Biest Troches: The Estrogen Blend Only Compounding Can Provide

Biest is a compounded blend of two estrogens, typically 20% estradiol and 80% estriol, that no single FDA-approved product replicates. Proponents argue estriol’s weaker activity offers a more balanced profile, though long-term safety data for Biest specifically remains limited. Dosing requires individualized titration guided by symptom response and serum estradiol levels. The 2026 patch shortage is pushing many previously stable patients toward Biest troches or creams, and providers should monitor for potential “Demonstrably Difficult to Compound” list actions affecting certain estradiol formulations.

Progesterone Troches: Understanding the High-Dose Reality

Progesterone troches require notably higher doses (200 to 400 mg/day versus 20 to 40 mg for creams) because much of the dose is swallowed rather than absorbed buccally. Swallowed progesterone undergoes first-pass metabolism, producing allopregnanolone metabolites with sedative effects, which is why bedtime dosing is often recommended. Because serum levels peak and fall within four to five hours, at least twice-daily dosing is needed for endometrial protection in women with a uterus. FDA-approved micronized progesterone (Prometrium) offers established pharmacokinetics; compounded troches offer customization but less equivalent evidence. Serum monitoring is essential, and salivary testing is unreliable due to oral contamination.

Testosterone Troches: Men’s and Women’s Health Applications

For women, testosterone troches (typically 0.5 to 2 mg/day) target libido, energy, cognition, and mood, though professional bodies advise against them for the reasons noted above. Providers should document clinical rationale and obtain informed consent. For men in andropause or on TRT, troches offer a non-injectable option, though FDA-approved topical testosterone should be considered first-line. Combination troches (testosterone + DHEA, testosterone + progesterone) provide genuine compounding rationale. Men’s health applications are expanding to include sildenafil, tadalafil, and vardenafil combination troches for sexual health, an underreported segment. Providers should note that the FDA is evaluating whether to restrict certain compounded testosterone formulations.

DHEA, Pregnenolone, and Combination BHRT Troches

DHEA is a precursor hormone that converts to estrogen and testosterone; compounded troches allow precise dosing unavailable in OTC supplements. Pregnenolone, a neurosteroid precursor, supports cognition and mood within balancing protocols. The unique value lies in combination troches delivering Biest + progesterone + testosterone + DHEA in individualized ratios impossible with any mix of FDA-approved products. Lab-guided dosing is essential to avoid over- or under-dosing any component, and Nationwide Compounding Rx® adjusts these formulas at each refill based on updated labs.

Beyond BHRT: Emerging Troche Applications in 2026

Troches are a versatile delivery platform, not just a BHRT vehicle. The applications below highlight where the market is expanding.

Ketamine Troches for Treatment-Resistant Depression and Chronic Pain

Ketamine, an FDA-approved anesthetic, is used off-label as a rapid-acting antidepressant. Compounded sublingual troches enable at-home maintenance between clinic infusions. A 2025 Duke University case report in Cureus documented clinically meaningful improvements in depression and anxiety scores after low-dose sublingual ketamine troches, with successful tapering of four psychotropic medications. Sublingual ketamine bypasses first-pass metabolism, achieving therapeutic plasma levels at lower doses than oral formulations. As a Schedule III controlled substance, it requires DEA-compliant prescribing, state-specific rules, and careful monitoring for dissociation and abuse potential, reinforcing the need for a pharmacy with controlled substance expertise.

GLP-1 and Peptide Troches: Semaglutide, Sermorelin, and the Regulatory Landscape

Semaglutide with B12 troches for weight management grew during GLP-1 injectable shortages but now face significant restrictions. A May 2026 Federal Register notice is evaluating semaglutide, tirzepatide, and liraglutide for the 503B bulks list. With brand shortages resolved in many markets, the FDA has restricted compounding of copies, so providers must verify current legal status before prescribing. Sermorelin troches, a growth hormone-releasing hormone analog, offer a non-injectable peptide option. This frontier demands a pharmacy that monitors FDA guidance in real time, consistent with Nationwide Compounding Rx®’s GLP-1/Peptide Support service line.

Troches for Special Populations: Pediatric, Geriatric, and Dysphagia Patients

Patients who cannot swallow pills, including elderly, post-surgical, and neurologically impaired individuals, benefit from troches as a non-swallowed alternative. Pediatric troches provide weight-specific dosing in kid-friendly flavors such as cherry and bubblegum, and Nationwide Compounding Rx® compounds for newborns through teens. Geriatric polypharmacy patients may consolidate medications into combination troches, and reduced GI absorption makes transmucosal delivery advantageous. Flavored medications for children and animal-friendly flavors also point to veterinary compounding capability.

The Regulatory Landscape Every Troche Patient and Provider Must Understand in 2026

The regulatory environment determines which troches are legally available, from which pharmacies, and for how long. Regulatory literacy is not optional.

503A vs. 503B: What the Distinction Means for Your Troche Prescription

503A pharmacies compound patient-specific medications from individual prescriptions under state board and USP oversight. 503B outsourcing facilities are FDA-registered, produce batches without patient-specific prescriptions, and follow federal CGMP standards. Most compounded troches come from 503A pharmacies. These pharmacies may only use APIs from FDA-inspected vendors complying with USP/NF monographs or the FDA’s approved bulk substances list. Effective January 7, 2025, the FDA stopped placing newly nominated bulk substances into interim categories, tightening the ingredient pipeline. If a current formulation’s bulk substance loses interim status, a pharmacy may be legally barred from continuing it.

The “Demonstrably Difficult to Compound” List: A Direct Threat to BHRT Troche Availability

These FDA lists restrict compounding of preparations posing safety risks or where commercial alternatives exist. Hormone pellets were added in 2024. In 2026, the FDA is evaluating certain testosterone and estradiol formulations for the “Demonstrably Difficult to Compound” list, which would eliminate 503A production of those forms. Patients relying on compounded testosterone or estradiol troches could lose access, so providers should document medical necessity and monitor FDA announcements. The 2026 med spa compliance guidance and NASEM consensus report add context to this pressure.

The SAFE Drugs Act of 2025 and What It Could Mean for Compounded Troches

H.R. 6509 proposes tighter oversight, including limits on 503A pharmacies compounding copies of commercially available drugs and mandatory annual FDA reporting for interstate compounding. If enacted, it could restrict troches for compounds with FDA-approved alternatives even in different delivery forms. As of September 2026, the bill is proposed but not enacted. Interstate reporting requirements would affect nationwide shippers, reinforcing the value of rigorous compliance. Nationwide Compounding Rx®’s regulatory compliance posture reflects continued 503A/503B implementation through updated reporting and adverse event monitoring. Understanding state regulations for compounding pharmacies is essential for both patients and providers navigating this landscape.

The Telehealth-to-Troche Patient Journey: From Online Consultation to Home Delivery

Telehealth is a major 2026 growth driver. A typical workflow proceeds as follows: (1) the patient schedules an online consultation; (2) the provider orders baseline labs; (3) the visit reviews symptoms and results; (4) the provider writes a specific troche prescription; (5) it transmits to the pharmacy; (6) the pharmacy compounds and ships; (7) follow-up labs guide refill adjustments.

Compounded troches require a valid prescription from a prescriber licensed in the patient’s state; controlled substances such as ketamine add DEA requirements. Nationwide Compounding Rx® adjusts BHRT formulas at each refill based on updated labs, a critical advantage for remote patients. Secure Provider and Patient Portals streamline submission, tracking, and refills, with a one to two business day turnaround and same-day pickup available for some medications for local Scottsdale patients. Leading pharmacies ship to multiple states; Nationwide uses a three-tier licensing system (fully licensed, non-sterile only, and sterile/non-sterile pending). Patients can learn more about the compounding pharmacy that ships nationwide to confirm availability in their state.

How to Write a Troche Prescription: A Provider Reference Guide

Essential elements include: patient name and date of birth; prescriber name with DEA/NPI; drug name(s) and strength(s); dosage form (troche/lozenge); base/vehicle if specified; quantity; dosing instructions (placement, dissolution time, frequency); refill authorization; and any flavor or allergen-free requirements.

Providers should always specify sublingual vs. buccal placement, as it affects absorption and counseling. For combination formulations, each ingredient and strength should be listed separately so the pharmacy can confirm compatibility. Including baseline hormone levels in the notes allows the pharmacy to flag dosing concerns. Prescriptions reach Nationwide Compounding Rx® via the secure Provider Portal, fax (480-699-5341), or phone (480-499-8379), following the Connect, Collaborate, Create, and Care framework. Providers are encouraged to contact the team with clinical questions before finalizing. A full overview of compounding pharmacy prescription requirements can help providers prepare accurate submissions.

Insurance, Cost, and Payment Options for Compounded Troches

Compounded troches are not FDA-approved and are not covered by most commercial insurance. However, HSA and FSA funds are generally eligible for provider-prescribed compounded medications, a meaningful offset. Out-of-pocket cost depends on the number of active ingredients, quantities, formulation complexity, and pharmacy overhead; multi-hormone combination troches cost more than single-ingredient ones. Commercial HRT may be cheaper when insured, but troches deliver customization that commercial products cannot. The 2026 patch shortage has complicated comparisons, sometimes making troches the only practical option. Patients should request a detailed estimate and confirm HSA/FSA eligibility. For a broader overview of compounding pharmacy insurance coverage options, patients can review what reimbursement pathways may apply. Nationwide Compounding Rx® does not publish pricing; contact the pharmacy directly for a quote.

What to Demand from a Quality Troches Compounding Pharmacy: The 2026 Checklist

Compounded troches are only as good as the pharmacy that makes them. Formulation accuracy, ingredient sourcing, and quality practices directly affect safety and outcomes. PCAB accreditation is held by fewer than 1% of U.S. pharmacies, making it a meaningful differentiator.

PCAB Accreditation: What It Is and Why It Matters

PCAB was established in 2007 by eight national pharmacy organizations and is the gold standard for compounding quality. It covers USP <795> (non-sterile), <797> (sterile), and <800> (hazardous drug handling), requiring on-site surveys, staff competency assessments, and documented quality systems. Surveys evaluate facility design, equipment calibration, ingredient sourcing, procedures, quality control testing, and adverse event reporting. State licensing is the legal minimum; PCAB goes well beyond it. Nationwide Compounding Rx® is PCAB accredited and USP 800 compliant. Patients and providers should verify accreditation directly through the PCAB website.

USP <795> Compliance and Non-Sterile Compounding Standards for Troches

Troches fall under USP <795>, covering personnel training, facility requirements, ingredient quality, procedures, beyond-use dating, and labeling. Key requirements include pharmaceutical-grade APIs from FDA-inspected vendors, calibrated equipment, and stability-based beyond-use dating. Patients should store troches as directed and not use them past that date. Homogeneity is critical: the active ingredient must be uniformly distributed so every unit doses consistently. Nationwide Compounding Rx® uses independent third-party testing to verify potency, sterility where applicable, and homogeneity. Rigorous quality control in compounding pharmacy practices underpin every finished preparation.

API Sourcing, Third-Party Testing, and the Quality Chain

APIs must come from FDA-inspected vendors and comply with USP/NF monographs or the approved bulk substances list. Providers and patients should ask: Can the pharmacy provide a Certificate of Analysis? Are its vendors FDA-inspected? Does it document vendor qualification? Independent third-party testing verifies actual versus labeled potency, contaminant-free preparations, and uniform distribution. Without proper sourcing and testing, a troche labeled 200 mg progesterone could contain far more or less, with direct clinical consequences. Understanding what pharmaceutical-grade ingredients mean in practice helps patients ask the right questions.

The Full Quality Checklist: Questions to Ask Any Troches Compounding Pharmacy

• Is the pharmacy PCAB accredited? (Verify at pcabaccreditation.org)
• Is it USP <795> and USP <800> compliant?
• Are APIs sourced exclusively from FDA-inspected vendors, with Certificates of Analysis available?
• Does it conduct independent third-party testing on finished preparations?
• What is the beyond-use dating policy, and is it stability-based?
• Is it licensed in the patient’s state for the required compounding type?
• What is the turnaround time, and is nationwide shipping offered?
• Is there a secure provider portal for submission and tracking?
• Does the team collaborate with prescribers on formulation optimization?
• How does it monitor and communicate FDA regulatory changes?

Nationwide Compounding Rx® meets all of these criteria: PCAB accredited, USP 800 compliant, FDA-cleared API sourcing, independent third-party testing, nationwide shipping, secure portals, and 40+ years of combined team experience.

Why Nationwide Compounding Rx® Is the Trusted Partner for Troches in 2026

The differentiators are concrete: PCAB accreditation (held by fewer than 1% of U.S. pharmacies), USP 800 compliance, independent third-party testing, FDA-cleared API sourcing, 40+ years of combined team experience, a one to two business day turnaround, and nationwide shipping.

Its BHRT specialization includes adjustable formulas at each refill based on updated labs, plus Biest, progesterone, testosterone, DHEA, pregnenolone, and combination troches. The provider partnership follows the Connect, Collaborate, Create, and Care framework, supported by a secure Provider Portal for submission, tracking, and direct communication. Patients benefit from a secure Patient Portal, multiple flavor options, allergen-free formulations, and same-day pickup availability locally.

The pharmacy is located at 14000 N. Hayden Rd., Suite 104, Scottsdale, AZ 85260; phone (480) 499-8379; Monday through Friday, 7:00 AM to 3:30 PM; nationwidecompounding.com. The team actively monitors FDA 503A/503B guidance, SAFE Drugs Act developments, and “Demonstrably Difficult to Compound” list updates. Notably, this is not a pharmacy that insists troches are always the best option. It helps patients and providers make genuinely informed decisions, then delivers the highest-quality formulation when a troche is the right choice.

Conclusion: Making an Informed Decision About Compounded Troches in 2026

Troches offer genuine advantages: rapid onset, high bioavailability, first-pass bypass, and combination formulations. They also carry real limitations, including peak-and-trough fluctuations, high progesterone doses from swallowing loss, and twice-daily dosing requirements. The right delivery form depends on the compound, clinical needs, lifestyle, and cost.

The regulatory landscape carries real risk. The January 2025 bulk substance policy change, the “Demonstrably Difficult to Compound” list threat, and the SAFE Drugs Act of 2025 all warrant ongoing attention. With fewer than 1% of U.S. pharmacies holding PCAB accreditation, choosing a quality compounder directly determines whether a troche delivers its labeled dose safely.

Market momentum is undeniable: HRT is compounding’s fastest-growing segment, the patch shortage is driving troche adoption, and telehealth is expanding access. Access without quality, however, is not progress. As new applications emerge, working with a pharmacy that combines clinical expertise, quality infrastructure, and regulatory vigilance remains the most important decision a patient or provider can make. Exploring the full range of specialty compounding pharmacy services available can help patients and providers identify the right formulation strategy for their specific needs.

Ready to Get Started? Connect with Nationwide Compounding Rx® Today

For patients: Those with a prescription for compounded troches, or who want to explore whether troches are right for their BHRT or other therapy, should contact Nationwide Compounding Rx®. Call (480) 499-8379, visit nationwidecompounding.com, or use the secure Patient Portal to manage accounts and refills.

For providers: Partner with a PCAB-accredited pharmacy that collaborates with your clinical team. Submit prescriptions through the secure Provider Portal, or call (480) 499-8379 to discuss formulation options, API sourcing documentation, and the Connect, Collaborate, Create, and Care partnership process.

Nationwide Compounding Rx® accepts prescriptions from telehealth providers and ships compounded troches nationwide (availability varies by state and medication type); verify state shipping availability at nationwidecompounding.com.

Contact: 14000 N. Hayden Rd., Suite 104, Scottsdale, AZ 85260 | Phone: (480) 499-8379 | Fax: (480) 699-5341 | Hours: Monday through Friday, 7:00 AM to 3:30 PM | Email inquiries answered within one business day.

PCAB Accredited. USP 800 Compliant. Independent Third-Party Tested. 40+ Years of Combined Team Experience. Nationwide Compounding Rx®, your partner in personalized medicine.